Efficacy of Nivolumab in Patients With Advanced Ocular or Mucosal Melanoma
Posted: Monday, November 11, 2019
Nivolumab is less effective in patients with ocular or mucosal melanoma than in patients with non-acral or acral cutaneous melanoma, according to a new open-label phase II trial. The study was published in The European Journal of Cancer by Paul Nathan, MD, of Mount Vernon Cancer Centre in London, and colleagues.
“Median overall survival was lowest in patients with ocular and mucosal melanoma,” the authors wrote.
The CheckMate 172 phase II trial enrolled 1,008 patients whose cancer had progressed on previous ipilimumab, including 723 patients with non-acral cutaneous melanoma, 55 with acral cutaneous melanoma, 103 with ocular melanoma, and 63 with mucosal melanoma. Patients received nivolumab every 2 weeks for up to 2 years.
The safety of the drug was similar across different melanoma subtypes, with no meaningful differences in the occurrence of grade 3 or higher adverse events. However, median overall survival was best for non-acral cutaneous melanoma (25.3 months) and acral cutaneous melanoma (25.8 months). Ocular melanoma and mucosal melanoma displayed lower median overall survival of 12.6 and 11.5 months, respectively. Likewise, the 18-month overall survival rates were higher for non-acral cutaneous melanoma (57.5%) and acral cutaneous melanoma (59.0%), and lower for ocular melanoma (34.8%) and mucosal melanoma (31.5%).
Disclosure: Visit ejcancer.com for disclosure information on the study authors.